Sleep Research
Sleep is characterized by altered consciousness, it is split into two distinct stages- rapid eye movement (REM) and non-REM. The circadian clock controls the pattern of sleep and wakefulness. It is regulated by the light levels, temperature, metabolites, neurotransmitters, neuropeptides, and neurohormones, which cause a daily fluctuation in expression levels of many sleep-related genes.
Sleep Research Products Targets
- Adenosine A2A Receptor (11)
- GABAB Receptor (28)
- 5-HT2C Receptor (23)
- 5-HT2B Receptor (12)
- 5-HT2A Receptor (25)
- Melatonin Receptor (10)
- GABAA-ρ Receptor (8)
- GABAA Receptor (66)
- Retinoic Acid-related Orphan Receptor (4)
- Rev-Erb Receptor (2)
- DREADD Ligands (1)
- D3 Receptor (12)
- 5-HT3 Receptor (39)
- D2 Receptor (14)
- Histamine H3 Receptor (22)
- Adenosine A1 Receptor (12)
- OX2 Receptor (4)
- OX1 Receptor (5)
Products for Sleep Research - Page 5
- Cat.No. Product Name Information/Activity
-
BCC7160
N6-Cyclopentyladenosine
N6-Cyclopentyladenosine (CPA) is a selective Adenosine A1 receptor agonist, with Ki values of 2.3 nM, 790 nM and 43 nM for human A1, A2A and A3 receptors, respectively.
-
BCC7716
(±)-5'-Chloro-5'-deoxy-ENBA
Highly selective A<sub>1</sub> agonist
-
BCC7215
GR 79236
GR79236 is a highly potent and selective adenosine A1 receptor agonist (Ki = 3.1 nM) that has analgesic and anti-inflammatory actions in humans and animals.
-
BCC7311
2'-MeCCPA
205171-12-6
-
BCC7374
SDZ WAG 994
130714-47-5
-
BCC6664
1,3-Dipropyl-8-phenylxanthine
85872-53-3
-
BCC6649
DPCPX
102146-07-6
-
BCC6124
KW 3902
Rolofylline (KW-3902) is a potent, selective adenosine A1 receptor antagonist that is under development for the treatment of patients with acute congestive heart failure and renal impairment. Rolofylline is metabolized primarily to the pharmacologically active M1-trans and M1-cis metabolites by cytochrome P450 (CYP450). Rolofylline is alleviating the presynaptic dysfunction and restores neuronal activity as well as dendritic spine levels in vitro, is an interesting candidate to combat the hypometabolism and neuronal dysfunction associated with Tau-induced neurodegenerative diseases.
-
BCC7240
PSB 36
524944-72-7
-
BCC7656
SLV 320
Derenofylline (SLV 320) is a potent, selective and orally active adenosine A1 receptor antagonist, with Ki values of 1 nM, 200 nM and 398 nM for human A1, A3 and A2A receptors respectively. Derenofylline suppresses cardiac fibrosis and attenuates albuminuria without affecting blood pressure in rats.


